An Alzheimer's drug developed by Swiss company Roche could not be proven in clinical trials to slow the progression of dementia, the pharmaceutical giant said Monday.
In a statement, Roche said the drug, gantenerumab, "did not meet their primary endpoint of slowing clinical decline" in a pair of studies conducted by the company. The identical studies, which were conducted with patients over the course of two years, were held in an effort to prove that gantenerumab could preserve certain functions in early Alzheimer's patients, including problem-solving skills, memory, and judgment.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
The best books of 2024 to give this ChristmasThe Week Recommends From Percival Everett to Rachel Clarke these are the critics' favourite books from 2024
-
Parmigianino: The Vision of St Jerome – masterpiece given 'new lease of life'The Week Recommends 'Spectacularly inventive' painting is back on display at the National Gallery
-
5 unidentifiable cartoons about drones over New JerseyCartoons Artists take on national priorities, national security, and more
-
Drugmakers paid pharmacy benefit managers to avoid restricting opioid prescriptionsUnder the radar The middlemen and gatekeepers of insurance coverage have been pocketing money in exchange for working with Big Pharma
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
-
Bird flu one mutuation from human threat, study findsSpeed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
-
Polycystic ovary syndrome: what it is, how it's treated and why it's often misunderstoodThe Explainer PCOS affects millions, but there is still no cure outside of treating symptoms separately
-
Dark chocolate tied to lower diabetes riskSpeed Read The findings were based on the diets of about 192,000 US adults over 34 years
-
The great departure: Texas OB-GYNs are leaving the Lone Star StateUnder the radar The state is suffering an exodus of health care professionals, creating more maternity care deserts
-
ADHD drugs shortage: what's behind it?The Explainer Supply chain issues and 'tripling' of prescriptions concerns GPs as problems getting medication become 'desperate'
-
Cannabinoid hyperemesis syndrome: a rare but troubling health risk for cannabis usersThe Explainer The illness is sending some chronic marijuana users to emergency care for painful persistent vomiting
